TABLE 5.
Francisella subunit vaccine candidates
| Antigen | Adjuvant | Dose, μg (route)a | Challenge strain | Boost | Challenge route (dose, CFU)b | Host mouse strain | Protection | Reference |
|---|---|---|---|---|---|---|---|---|
| Ethanol-inactivated LVS | Freund's adjuvant | 20 (i.p.) | Schu S4 | No | i.n. (40) | C3H/HeN | Yes | 94 |
| LPS | Freund's adjuvant | 20 (i.p.) | Schu S4 | No | i.n. (40) | C3H/HeN | No | 94 |
| Outer membrane proteins | Freund's adjuvant | 20 (i.p.) | Schu S4 | No | i.n. (40) | C3H/HeN | Yes | 94 |
| LPS | Freund's adjuvant | 50 (s.c.) | LVS | Yes | i.p. (2.5 × 106) | BALB/c | Yes | 73 |
| OMP | Freund's adjuvant | 100 | LVS | Yes | i.p. (2.5 × 106) | BALB/c | Yes | 73 |
| LPS | Bovine serum albumin | 20 (s.c.) | Type B no. 108 | No | i.d. (80) | BALB/c | Yes | 42 |
| Aerosol (30) | BALB/c | No | 42 | |||||
| Type A no. 33 | No | i.d. (60) | BALB/c | No | 42 | |||
| Aerosol (50) | BALB/c | No | 42 |
a
i.p., intraperitoneal; s.c., subcutaneous.
b
i.d., intradermal; i.n., intranasal.